Titre : | Circulating 25-Hydroxyvitamin D and the Risk of Rarer Cancers : Design and Methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers : Anticancer Vitamins du Jour : The ABCED's So Far. (2010) |
Auteurs : | Lisa GALLICCHIO ; Christian-C ABNET ; Demetrius ALBANES ; Kimberly Bertrand ; Wong-Ho CHOW ; Dmichal FREEDMAN ; Susan-E HANKINSON ; Patricia HARTGE ; Virginia HARTMULLER ; Chinonye HARVEY ; Richard-B HAYES ; Kathy-J HELZLSOUER ; Ronald-L HORST ; . KAI YU ; Karen-L KOENIG ; Laurence-N KOLONEL ; Francine LADEN ; Marjorie-L MCCULLOUGH ; Dominick PARISI ; Mark-P PURDUE ; Xiao-Ou SHU ; Kirk SNYDER ; Rachael-Z STOLZENBERG-SOLOMON ; Shelley-S TWOROGER ; Arti VARANASI ; Jarmo VIRTAMO ; . WEI ZHENG ; Stephanie-J WEINSTEIN ; Lynne-R WILKENS ; Yong-Bing XIANG ; Anne ZELENIUCH-JACQUOTTE ; Department of Environmental Medicine. School of Medicine. New York University. New York. NY. USA ; Division of Epidemiology. Department of Medicine. Vanderbilt Epidemiology Center. Vanderbilt-Ingram Cancer Center. School of Medicine. Vanderbilt University. Nashville. TN. USA ; Epidemiology Program. Cancer Research Center. University of Hawaii. Honolulu. HI. USA ; Information Management Services. Inc. Silver Spring. MD. USA ; New York University Cancer Institute. New York. NY. USA |
Type de document : | Article |
Dans : | American journal of epidemiology (vol. 172, n° 1, 2010) |
Pagination : | 10-20 |
Langues: | Anglais |
Mots-clés : | Cancer ; Facteur risque ; Risque ; Méthode ; Méthodologie ; Vitamine D ; Enquête cas témoin ; Epidémiologie ; Etude prospective |
Résumé : | [BDSP. Notice produite par INIST-CNRS lp9R0xAB. Diffusion soumise à autorisation]. The Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP), a consortium of 10 prospective cohort studies from the United States, Finland, and China, was formed to examine the associations between circulating 25-hydroxyvitamin D (25 (OH) D) concentrations and the risk of rarer cancers. Cases (total n=5,491) included incident primary endometrial (n=830), kidney (n=775), ovarian (n=516), pancreatic (n=952), and upper gastrointestinal tract (n=1,065) cancers and non-Hodgkin lymphoma (n=1,353) diagnosed in the participating cohorts. At least 1 control was matched to each case on age, date of blood collection (1974-2006), sex, and race/ethnicity (n=6,714). Covariate data were obtained from each cohort in a standardized manner. The majority of the serum or plasma samples were assayed in a central laboratory using a direct, competitive chemiluminescence immunoassay on the DiaSorin LIAISON platform (DiaSorin, Inc., Stillwater, Minnesota). Masked quality control samples included serum standards from the US National Institute of Standards and Technology. Conditional logistic regression analyses were conducted using clinically defined cutpoints, with 50- |